Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Public ClinicalTrials.gov record NCT04468061. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)
Study identification
- NCT ID
- NCT04468061
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Enrollment
- 110 participants
Conditions and interventions
Interventions
- Pembrolizumab Drug
- Sacituzumab Govitecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 19, 2020
- Primary completion
- Mar 31, 2027
- Completion
- Mar 31, 2029
- Last update posted
- Apr 28, 2026
2020 – 2029
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stamford Hospital | Stamford | Connecticut | 06904 | Recruiting |
| Miami Cancer Institute at Baptist Health (Kendall) | Miami | Florida | 33176 | Recruiting |
| Miami Cancer Institute at Baptist Health | Plantation | Florida | 33324 | Recruiting |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | Recruiting |
| Eastern Maine Medical Center | Brewer | Maine | 04412 | Recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| DFCI @ Foxborough | Foxborough | Massachusetts | 02035 | Recruiting |
| DFCI @ Milford Regional Hospital | Milford | Massachusetts | 01757 | Recruiting |
| DF/BWCC in Clinical Affiliation with South Shore Hospital | South Weymouth | Massachusetts | 02190 | Recruiting |
| The University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | Recruiting |
| The Christ Hospital Cancer Center | Cincinnati | Ohio | 45219 | Recruiting |
| Ohio State University Medical Center | Columbus | Ohio | 43212 | Recruiting |
| University of Pennsylvania-Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | Recruiting |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | Recruiting |
| Sarah Cannon Research Institute | Chattanooga | Tennessee | 37404 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04468061, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2026 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04468061 live on ClinicalTrials.gov.